A novel bispecific immunotherapy developed by Roche AG to target pancreatic cancer showed promising results combined with radiation therapy in preclinical trials carried out at the University of Colorado. Read More
Acute lung injury (ALI) is a respiratory disease characterized by increased lung epithelial permeability, inflammatory cell infiltration and edema with a more than 40% mortality rate. Researchers from Wenzhou Medical University and colleagues reported the design and synthesis of [I], a novel cinnamic acid (CIN) derivative that targets the interaction of MD-2 protein and LPS showing anti-inflammatory activity. Read More
Vyne Therapeutics Inc. has selected a development candidate, VYN-202, for its oral BD2-selective bromodomain and extra-terminal (BET) inhibitor program for the treatment of immuno-inflammatory conditions. Read More
Salarius Pharmaceuticals Inc. has completed two GLP toxicology studies with its targeted protein degrader SP-3164, with no unexpected safety findings reported. These results will be included in an IND application that the company plans to submit to the FDA this quarter. Read More
Researchers from Fochon Biosciences Ltd. have reported the discovery and preclinical evaluation of a novel second-generation B-cell lymphoma 2 (BCL2) inhibitor, FCN-683, being developed for the treatment of B-cell malignancies. FCN-683 showed the ability to potently and selectively inhibit both wild-type BCL2 (IC50=0.11 nM) and multiple clinically relevant venetoclax-resistant mutants, including G101V, D103E/V/Y, F104L, A113G, R129L and V156D. Read More
Atsena Therapeutics Inc.’s IND application for ATSN-201 has been cleared by the FDA enabling the company to initiate a phase I/II trial in patients with X-linked retinoschisis (XLRS) caused by pathogenic or likely pathogenic mutations in RS1. Read More
Prostaglandin E2 (PGE2) regulates inflammation and the tumor microenvironment, thought to happen through engagement with the E-type prostanoid EP2 and EP4 receptors, exerting immunosuppression in the tumor microenvironment. The simultaneous blockade of EP2 and EP4 – not blocking either alone – is needed to overcome this immunosuppressor effect. Read More
Initial Therapeutics Inc. has launched with a focus on developing medicines that block difficult-to-drug protein targets with a new mode of action – selective termination of protein synthesis (STOPS). Read More
Macrophages, a cell type involved in the inflammatory response, are also responsible for collagen deposition in lung and liver fibrosis. In a recently published study, researchers identified a subpopulation of profibrotic macrophages. Read More
State University of New Jersey (Rutgers) has divulged flavonoids acting as GABA-A receptor positive allosteric modulators (PAMs) reported to be useful for the treatment of alcoholism. Read More
Onquality Pharmaceuticals LLC has received FDA clearance of its IND application for OQL-036, a potential prophylactic treatment for capecitabine-induced hand-foot syndrome (HFS). Read More
Vincerx Pharma Inc. has described drug conjugates comprising prodrugs of cyclin-dependent kinase 9 (CDK9) inhibitors covalently linked to an integrin binding moiety through a linker. They are reported to be useful for the treatment of cancer, autoimmune disease, cardiac hypertrophy and macular degeneration. Read More
